Do patients with metastatic urothelial carcinoma benefit from docetaxel as second-line chemotherapy?

R. Morales-Barrera, C. Suárez, C. Valverde, I. Nuñez, X. Maldonado, J. Morote, J. Carles

Research output: Contribution to journalArticleResearchpeer-review

8 Citations (Scopus)


Purpose: To evaluate the efficacy and toxicity of docetaxel regimen as second-line after failure of a platinum-based chemotherapy. Methods: Between May 2005 and June 2008, we retrospectively analyzed the data of 22 patients who had evidence of disease progression after one prior platinum-based regimen for metastatic urothelial carcinoma. Patients were treated with two different docetaxel dose schedules: (1) docetaxel 60 mg/m2 every 21 days for unfit patients or (2) docetaxel 75 mg/m2 every 21 days for fit patients. Results: Median number of docetaxel cycles was three. Overall disease control rate was 18 %. Of the 22 patients, no patient achieved complete or partial response and four patients had stable disease. Median progression-free survival was 1.67 months and median overall survival was 3.12 months. Neutropenia was the most common adverse event. Conclusions: This study identifies that docetaxel as second-line chemotherapy has low activity and was associated with significant toxicity. © 2013 Federación de Sociedades Españolas de Oncología (FESEO).
Original languageEnglish
Pages (from-to)102-106
JournalClinical and Translational Oncology
Issue number1
Publication statusPublished - 1 Jan 2014


  • Docetaxel
  • Metastatic
  • Second-line therapy
  • Urothelial carcinoma


Dive into the research topics of 'Do patients with metastatic urothelial carcinoma benefit from docetaxel as second-line chemotherapy?'. Together they form a unique fingerprint.

Cite this